Background:Diagnostic panels based on multiple biomarkers and clinical characteristics are considered more favorable than individual biomarker to diagnose hepatocellular carcinoma(HCC).Based on age,sex,alpha-fetoprote...Background:Diagnostic panels based on multiple biomarkers and clinical characteristics are considered more favorable than individual biomarker to diagnose hepatocellular carcinoma(HCC).Based on age,sex,alpha-fetoprotein(AFP),and protein induced by vitamin K absence II(PIVKA-II)with/without AFP-L3,ASAP and GALAD models are potential diagnostic panels.The diagnostic performances of these two panels were compared relative to HCC detection among patients with various etiologies of chronic liver diseases(CLDs).Methods:A multicenter case-control study recruited CLDs patients with and without HCC from 14 Chi-nese hospitals.The etiologies of CLDs included hepatitis B virus(HBV),hepatitis C virus(HCV),alcoholic liver disease(ALD),and nonalcoholic fatty liver disease(NAFLD).Using area under the receiver operating characteristic curve(AUC)values,the diagnostic performances of ASAP and GALAD models were com-pared to detect HCC among patients with various etiologies of CLDs.Results:Among 248 HCC patients and 722 CLD controls,the ASAP model demonstrated the highest AUC(0.886)to detect HCC at any stage,outperforming the GALAD model(0.853,P=0.001),as well as any individual biomarker(0.687-0.799,all P<0.001).In the subgroup analysis of various CLDs etiologies,the ASAP model outperformed the GALAD model to HCC independent of CLDs etiology.In addition,the ASAP model performed better in detecting early-stage(BCLC stage 0/A)HCC versus the GALAD model.Conclusions:Despite using one less laboratory variable(AFP-L3),the ASAP model demonstrated better diagnostic performance than the GALAD model to detect all-stage HCC among patients with various eti-ologies of CLDs-related HCC.展开更多
BACKGROUND The GALAD score has improved early hepatocellular carcinoma(HCC)detection rate.The role of the GALAD score in staging and predicting tumor characteristics or clinical outcome of HCC remains of particular in...BACKGROUND The GALAD score has improved early hepatocellular carcinoma(HCC)detection rate.The role of the GALAD score in staging and predicting tumor characteristics or clinical outcome of HCC remains of particular interest.AIM To determine the diagnostic/prognostic performances of the GALAD score at various phases of initial diagnosis,tumor features,and 1-year mortality of HCC and compare the performance of the GALAD score with those of other serum biomarkers.METHODS This prospective,diagnostic/prognostic study was conducted among patients with newly diagnosed HCC at the liver center of Vajira Hospital.Eligible patients had HCC staging allocation using the Barcelona Clinic Liver Cancer(BCLC)categorization.Demographics,HCC etiology,and HCC features were recorded.Biomarkers and the GALAD score were obtained at baseline.The performance of the GALAD score and biomarkers were prospectively assessed.RESULTS Exactly 115 individuals were diagnosed with HCC.The GALAD score increased with disease severity.Between BCLC-0/A and BCLC-B/C/D,the GALAD score predicted HCC staging with an area under the curve(AUC)of 0.868(95%CI:0.80–0.93).For identifying the curative HCC,the AUC of GALAD score was significantly higher than that of Alpha-fetoprotein(AFP)(0.753)and Lens culinaris agglutinin-reactive fraction of AFP-L3(0.706),and as good as that of Protein induced by vitamin K absence-II(PIVKA-II)(0.897).For detecting aggressive features,the GALAD score gave an AUC of 0.839(95%CI:0.75–0.92)and significantly outperformed compared to that of AFP(0.761)and AFP-L3(0.697),with a trend of superiority to that of PIVKA-II(0.772).The performance to predict 1-year mortality of GALAD score(AUC:0.711,95%CI:0.60–0.82)was better than that of AFP(0.541)and as good as that of PIVKA-II(0.736).The optimal cutoff value of GALAD score was≥6.83,with a specificity of 72.63%for exhibiting substantial reduction in the 1-year mortality.CONCLUSION The GALAD model can diagnose HCC at the curative stage,including the characteristic of advanced disease,more than that by AFP and AFP-L3,but not PIVKA-II.The GALAD score can be used to predict the 1-year mortality of HCC.展开更多
目的基于GALAD模型分析高尔基体糖蛋白-73(Golgi protein 73,GP73)和肝脏硬度测量值(liver stiffness measurement,LSM)在丙型肝炎病毒(hepatitis C virus,HCV)相关肝细胞癌(hepatocellular carcinoma,HCC)患者中表达及诊断价值。方法选...目的基于GALAD模型分析高尔基体糖蛋白-73(Golgi protein 73,GP73)和肝脏硬度测量值(liver stiffness measurement,LSM)在丙型肝炎病毒(hepatitis C virus,HCV)相关肝细胞癌(hepatocellular carcinoma,HCC)患者中表达及诊断价值。方法选取2019年1月至2022年1月西安交通大学第一附属医院榆林医院收治的75例慢性HCV感染并确诊HCC患者(HCC组)和85例HCV感染非HCC患者(对照组)作为研究对象。采用全自动生化仪检测两组患者肝功能生化指标;采用全自动化学发光免疫分析仪分析两组患者甲胎蛋白(α-fetoprotein,AFP)、甲胎蛋白异构体L3(α-fetoprotein-L3,AFP-L3)、异常凝血酶原(des-γ-carboxy prothrombin,DCP)及GP73水平,并根据公式计算GALAD模型得分;采用肝纤维化无创扫描仪测量LSM;采用受试者工作特征曲线分析HCC诊断价值;采用Pearson相关方法进行相关性分析。结果HCC组患者肝功能指标、AFP、DCP、AFP-L3、LSM、GP73水平及GALAD模型评分均显著高于对照组(均P<0.05);HCC组患者不同肿瘤分期亚组AFP、DCP、AFP-L3、LSM、GP73水平及GALAD模型评分比较差异均有统计学意义(均P<0.05),且分期越晚指标水平和GALAD模型评分越高,各分期亚组间差异均有统计学意义(均P<0.05)。相关性分析显示,LSM、GP73水平与GALAD模型评分均呈线性正相关(r=0.622,P<0.001;r=0.532,P<0.001)。LSM、GP73及GALAD三项联合诊断HCC的曲线下面积为0.933,检测敏感度为94.56%,特异度为83.23%,均显著高于单独诊断(均P<0.05)。结论GALAD模型在HCV相关HCC诊断中显示了良好的效能,LSM、GP73作为HCC诊断标志物与GALAD模型评分呈正相关,且联合GALAD模型对HCC表现出更好的诊断效能。展开更多
BACKGROUND Chronic liver disease(CLD)causes approximately two million deaths each year,and its clinical diagnosis and management remain challenging.Ultrasound is currently the most widely used technique for disease de...BACKGROUND Chronic liver disease(CLD)causes approximately two million deaths each year,and its clinical diagnosis and management remain challenging.Ultrasound is currently the most widely used technique for disease detection.AIM To propose a practical cut-off value for identifying patients with hepatocellular carcinoma(HCC)among those with compensated advanced CLD or healthy individuals using the GALAD score,an algorithm based on a formula that incorporates gender,age,serum alpha-fetoprotein(AFP),AFP-L3,and des-gamma-carboxy prothrombin values.METHODS This cross-sectional analysis was conducted using prospectively collected data from five cohorts(n=1431)comprising healthy individuals,cirrhosis,and HCC patients.These subjects were enrolled from an Italian retrospective cohort,including patients from the IRCCS“Saverio de Bellis”,Department of Gastroenterology,the University of Modena and Reggio Emilia Gastroenterology Department,and the Padua University Hospital and the Department of Gastroenterology,Hepatology,Infectious diseases and Endocrinology,Hannover Medical School.RESULTS Using healthy subjects as reference,a GALAD score cut-off of-1.67 identified HCC with a sensitivity of 89.77%and specificity of 97.59%.Individuals with GALAD values>-1.67 exhibited a moderate to very high probability(over 90%)of having HCC.When cirrhotic patients were used as the reference category,a cut-off of-0.77 yielded a sensitivity of 78.17%and a specificity of 89.55%.CONCLUSION We strongly recommend incorporating this GALAD cut-off into clinical guidelines for the screening of patients with a compensated advanced CLD who are at high risk of developing HCC.Given the rapid global rise in metabolic-associated steatotic liver disease(MASLD)-related CLD,future research should prioritize larger MASLD cohorts to establish the most appropriate GALAD cut-off for diagnostic use,compared to healthy controls and to patients with other forms of CLD.展开更多
Background and Aims:Early detection of hepatocellular carcinoma(HCC)is crucial for improving survival in patients with chronic hepatitis.The GALAD algorithm combines gen-der(biological sex),age,α-fetoprotein(AFP),Len...Background and Aims:Early detection of hepatocellular carcinoma(HCC)is crucial for improving survival in patients with chronic hepatitis.The GALAD algorithm combines gen-der(biological sex),age,α-fetoprotein(AFP),Lens culinaris agglutinin-reactive fraction of AFP(AFP-L3),and protein in-duced by vitamin K absence or antagonist-II(PIVKA-II)for HCC detection.Similarly,the GAAD algorithm incorporates gender(biological sex),age,AFP,and PIVKA-II.This study aimed to assess the clinical utility of AFP-L3 in the GALAD algorithm and its potential synergies with ultrasound.We compared the clinical performance of GALAD with GAAD;AFP;AFP-L3;and PIVKA-II,with or without ultrasound,in Taiwan residents adults.Methods:A total of 439 serum samples were analyzed using a Cobas®e 601 analyzer(healthy con-trols,n=200;chronic liver disease controls,n=177;HCC cases,n=62).Performance was assessed through receiver operating characteristic curve analyses to calculate the area under the curve.Results:The area under the curve for dif-ferentiating early-stage HCC from patients with chronic liver disease was optimal for PIVKA-II(84.9%),GAAD(79.8%),and GALAD(79.4%),with slightly improved performance for detecting all-stage HCC.Clinical performance was unaffected by disease stage or etiology.Sensitivity for early-stage HCC was highest for GAAD(57.6%)and GALAD(57.6%).Sen-sitivity for each strategy was further enhanced when com-bined with ultrasound,regardless of disease stage or etiology(P<0.01).Conclusions:These findings indicate that the role of AFP-L3 in the GALAD algorithm is minimal,supporting the use of GAAD for HCC detection.A combination of GAAD,GALAD,or PIVKA-II with ultrasound may improve diagnostic efficiency compared with recommended strategies.展开更多
Background and Aims:Strategies for detection of early hepatocellular carcinoma(HCC)are still limited.The GALAD score is a serum biomarker-based model designed to predict the probability of having HCC.We aimed to asses...Background and Aims:Strategies for detection of early hepatocellular carcinoma(HCC)are still limited.The GALAD score is a serum biomarker-based model designed to predict the probability of having HCC.We aimed to assess the ability of GALAD score to diagnose early HCC and its validity to follow patients after local ablation therapy.Methods:This multicenter prospective study included 108 patients in two groups,58 HCC patients(67 focal lesions)with local ablative therapy(study group),and a control group of 50 patients with liver cirrhosis.The GALAD scores of the study and control groups,and of the HCC patients before and after ablative therapy were compared.Results:Most patients were men(74.1%in study group and 76%in controls)with hepatitis C virus infection(98.30%in the study group,and 94%in controls).GALAD scores were significantly higher in HCC patients than in those with benign cirrhosis(2.65 vs.−0.37,p=0.001).Ablative therapy was successful in 94.4%of focal lesions<2 cm,and in 86.10%of 2–5 cm lesions.The GALAD score was also significantly lower at 1 month after ablation in patients with well-ablated tumors(2.19 vs.0.98,p=0.001).The best cutoff values of GALAD score for diagnosis of early HCC,and for prediction of well ablation of HCC were 0.74 and≤3.31(areas under the curve of 0.92 and 0.75,sensitivities of 84.48%and 76.19%,specificities of 89.13%and 83.33%,positive predictive values of 90.74%and 94.1%,and negative predictive values of 82%and 35.7%respectively).Conclusion:The GALAD score was effective for the diagnosis of early HCC and for followup after ablative therapy.展开更多
Background and aims:The ASAP and GALAD scores are widely used diagnostic models for detecting hepatocellular carcinoma(HCC),incorporating factors such as sex,age,alpha-fetoprotein(AFP),protein induced by vitamin K abs...Background and aims:The ASAP and GALAD scores are widely used diagnostic models for detecting hepatocellular carcinoma(HCC),incorporating factors such as sex,age,alpha-fetoprotein(AFP),protein induced by vitamin K absence or antagonist-Ⅱ(PIVKA-Ⅱ),and lens culinaris agglutinin-reactive fraction of AFP(AFP-L3%).This study compares the diagnostic efficacy of the ASAP and GALAD scores in the early detection of HCC in patients with non-alcoholic fatty liver disease(NAFLD).Methods:NAFLD patients with and without HCC were recruited from 12 Chinese tertiary hospitals.Serum levels of AFP,PIVKA-II,and AFP-L3%were measured.The diagnostic accuracy of individual biomarkers,the ASAP score,and the GALAD score in detecting NAFLD-HCC at various stages was evaluated using receiver operating characteristic(ROC)curves and area under the curve(AUC)values.Results:In a cohort of 147 NAFLD-HCC cases and 460 NAFLD controls,both the ASAP and GALAD scores outperformed individual biomarkers in detecting NAFLD-HCC.The ASAP score demonstrated a high AUC of 0.910(sensitivity:80.3%,specificity:92.8%)for identifying NAFLD-HCC at all stages,surpassing AFP(AUC:0.716,P<0.001),PIVKA-II(AUC:0.849,P<0.001),AFP-L3%(AUC:0.663,P<0.001),and the GALAD score(AUC:0.882,P?0.014).Comparable results were observed for early-stage NAFLD-HCC and for detecting HCC in NAFLD patients with or without cirrhosis.Conclusion:The ASAP score,which excludes the AFP-L3%indicator,demonstrated superior performance in differentiating NAFLD-HCC compared to the GALAD score,suggesting its potential for early screening of HCC in NAFLD patients.展开更多
基金supported by grants from the National Natural Science Foundation of China(81972726 and 82273074)Abbott Diagnostics(ADD-China-2016).
文摘Background:Diagnostic panels based on multiple biomarkers and clinical characteristics are considered more favorable than individual biomarker to diagnose hepatocellular carcinoma(HCC).Based on age,sex,alpha-fetoprotein(AFP),and protein induced by vitamin K absence II(PIVKA-II)with/without AFP-L3,ASAP and GALAD models are potential diagnostic panels.The diagnostic performances of these two panels were compared relative to HCC detection among patients with various etiologies of chronic liver diseases(CLDs).Methods:A multicenter case-control study recruited CLDs patients with and without HCC from 14 Chi-nese hospitals.The etiologies of CLDs included hepatitis B virus(HBV),hepatitis C virus(HCV),alcoholic liver disease(ALD),and nonalcoholic fatty liver disease(NAFLD).Using area under the receiver operating characteristic curve(AUC)values,the diagnostic performances of ASAP and GALAD models were com-pared to detect HCC among patients with various etiologies of CLDs.Results:Among 248 HCC patients and 722 CLD controls,the ASAP model demonstrated the highest AUC(0.886)to detect HCC at any stage,outperforming the GALAD model(0.853,P=0.001),as well as any individual biomarker(0.687-0.799,all P<0.001).In the subgroup analysis of various CLDs etiologies,the ASAP model outperformed the GALAD model to HCC independent of CLDs etiology.In addition,the ASAP model performed better in detecting early-stage(BCLC stage 0/A)HCC versus the GALAD model.Conclusions:Despite using one less laboratory variable(AFP-L3),the ASAP model demonstrated better diagnostic performance than the GALAD model to detect all-stage HCC among patients with various eti-ologies of CLDs-related HCC.
基金The study was approved by the Institutional Review Board of the Faculty of Medicine Vajira Hospital(No.COA 165/2564).
文摘BACKGROUND The GALAD score has improved early hepatocellular carcinoma(HCC)detection rate.The role of the GALAD score in staging and predicting tumor characteristics or clinical outcome of HCC remains of particular interest.AIM To determine the diagnostic/prognostic performances of the GALAD score at various phases of initial diagnosis,tumor features,and 1-year mortality of HCC and compare the performance of the GALAD score with those of other serum biomarkers.METHODS This prospective,diagnostic/prognostic study was conducted among patients with newly diagnosed HCC at the liver center of Vajira Hospital.Eligible patients had HCC staging allocation using the Barcelona Clinic Liver Cancer(BCLC)categorization.Demographics,HCC etiology,and HCC features were recorded.Biomarkers and the GALAD score were obtained at baseline.The performance of the GALAD score and biomarkers were prospectively assessed.RESULTS Exactly 115 individuals were diagnosed with HCC.The GALAD score increased with disease severity.Between BCLC-0/A and BCLC-B/C/D,the GALAD score predicted HCC staging with an area under the curve(AUC)of 0.868(95%CI:0.80–0.93).For identifying the curative HCC,the AUC of GALAD score was significantly higher than that of Alpha-fetoprotein(AFP)(0.753)and Lens culinaris agglutinin-reactive fraction of AFP-L3(0.706),and as good as that of Protein induced by vitamin K absence-II(PIVKA-II)(0.897).For detecting aggressive features,the GALAD score gave an AUC of 0.839(95%CI:0.75–0.92)and significantly outperformed compared to that of AFP(0.761)and AFP-L3(0.697),with a trend of superiority to that of PIVKA-II(0.772).The performance to predict 1-year mortality of GALAD score(AUC:0.711,95%CI:0.60–0.82)was better than that of AFP(0.541)and as good as that of PIVKA-II(0.736).The optimal cutoff value of GALAD score was≥6.83,with a specificity of 72.63%for exhibiting substantial reduction in the 1-year mortality.CONCLUSION The GALAD model can diagnose HCC at the curative stage,including the characteristic of advanced disease,more than that by AFP and AFP-L3,but not PIVKA-II.The GALAD score can be used to predict the 1-year mortality of HCC.
文摘目的基于GALAD模型分析高尔基体糖蛋白-73(Golgi protein 73,GP73)和肝脏硬度测量值(liver stiffness measurement,LSM)在丙型肝炎病毒(hepatitis C virus,HCV)相关肝细胞癌(hepatocellular carcinoma,HCC)患者中表达及诊断价值。方法选取2019年1月至2022年1月西安交通大学第一附属医院榆林医院收治的75例慢性HCV感染并确诊HCC患者(HCC组)和85例HCV感染非HCC患者(对照组)作为研究对象。采用全自动生化仪检测两组患者肝功能生化指标;采用全自动化学发光免疫分析仪分析两组患者甲胎蛋白(α-fetoprotein,AFP)、甲胎蛋白异构体L3(α-fetoprotein-L3,AFP-L3)、异常凝血酶原(des-γ-carboxy prothrombin,DCP)及GP73水平,并根据公式计算GALAD模型得分;采用肝纤维化无创扫描仪测量LSM;采用受试者工作特征曲线分析HCC诊断价值;采用Pearson相关方法进行相关性分析。结果HCC组患者肝功能指标、AFP、DCP、AFP-L3、LSM、GP73水平及GALAD模型评分均显著高于对照组(均P<0.05);HCC组患者不同肿瘤分期亚组AFP、DCP、AFP-L3、LSM、GP73水平及GALAD模型评分比较差异均有统计学意义(均P<0.05),且分期越晚指标水平和GALAD模型评分越高,各分期亚组间差异均有统计学意义(均P<0.05)。相关性分析显示,LSM、GP73水平与GALAD模型评分均呈线性正相关(r=0.622,P<0.001;r=0.532,P<0.001)。LSM、GP73及GALAD三项联合诊断HCC的曲线下面积为0.933,检测敏感度为94.56%,特异度为83.23%,均显著高于单独诊断(均P<0.05)。结论GALAD模型在HCV相关HCC诊断中显示了良好的效能,LSM、GP73作为HCC诊断标志物与GALAD模型评分呈正相关,且联合GALAD模型对HCC表现出更好的诊断效能。
文摘BACKGROUND Chronic liver disease(CLD)causes approximately two million deaths each year,and its clinical diagnosis and management remain challenging.Ultrasound is currently the most widely used technique for disease detection.AIM To propose a practical cut-off value for identifying patients with hepatocellular carcinoma(HCC)among those with compensated advanced CLD or healthy individuals using the GALAD score,an algorithm based on a formula that incorporates gender,age,serum alpha-fetoprotein(AFP),AFP-L3,and des-gamma-carboxy prothrombin values.METHODS This cross-sectional analysis was conducted using prospectively collected data from five cohorts(n=1431)comprising healthy individuals,cirrhosis,and HCC patients.These subjects were enrolled from an Italian retrospective cohort,including patients from the IRCCS“Saverio de Bellis”,Department of Gastroenterology,the University of Modena and Reggio Emilia Gastroenterology Department,and the Padua University Hospital and the Department of Gastroenterology,Hepatology,Infectious diseases and Endocrinology,Hannover Medical School.RESULTS Using healthy subjects as reference,a GALAD score cut-off of-1.67 identified HCC with a sensitivity of 89.77%and specificity of 97.59%.Individuals with GALAD values>-1.67 exhibited a moderate to very high probability(over 90%)of having HCC.When cirrhotic patients were used as the reference category,a cut-off of-0.77 yielded a sensitivity of 78.17%and a specificity of 89.55%.CONCLUSION We strongly recommend incorporating this GALAD cut-off into clinical guidelines for the screening of patients with a compensated advanced CLD who are at high risk of developing HCC.Given the rapid global rise in metabolic-associated steatotic liver disease(MASLD)-related CLD,future research should prioritize larger MASLD cohorts to establish the most appropriate GALAD cut-off for diagnostic use,compared to healthy controls and to patients with other forms of CLD.
基金funded by Roche Diagnostics GmbH and partly supported by the“Center of Excellence for Metabolic Associated Fatty Liver Disease,National Sun Yat-sen University,Kaohsiung”,under The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education in Taiwan.
文摘Background and Aims:Early detection of hepatocellular carcinoma(HCC)is crucial for improving survival in patients with chronic hepatitis.The GALAD algorithm combines gen-der(biological sex),age,α-fetoprotein(AFP),Lens culinaris agglutinin-reactive fraction of AFP(AFP-L3),and protein in-duced by vitamin K absence or antagonist-II(PIVKA-II)for HCC detection.Similarly,the GAAD algorithm incorporates gender(biological sex),age,AFP,and PIVKA-II.This study aimed to assess the clinical utility of AFP-L3 in the GALAD algorithm and its potential synergies with ultrasound.We compared the clinical performance of GALAD with GAAD;AFP;AFP-L3;and PIVKA-II,with or without ultrasound,in Taiwan residents adults.Methods:A total of 439 serum samples were analyzed using a Cobas®e 601 analyzer(healthy con-trols,n=200;chronic liver disease controls,n=177;HCC cases,n=62).Performance was assessed through receiver operating characteristic curve analyses to calculate the area under the curve.Results:The area under the curve for dif-ferentiating early-stage HCC from patients with chronic liver disease was optimal for PIVKA-II(84.9%),GAAD(79.8%),and GALAD(79.4%),with slightly improved performance for detecting all-stage HCC.Clinical performance was unaffected by disease stage or etiology.Sensitivity for early-stage HCC was highest for GAAD(57.6%)and GALAD(57.6%).Sen-sitivity for each strategy was further enhanced when com-bined with ultrasound,regardless of disease stage or etiology(P<0.01).Conclusions:These findings indicate that the role of AFP-L3 in the GALAD algorithm is minimal,supporting the use of GAAD for HCC detection.A combination of GAAD,GALAD,or PIVKA-II with ultrasound may improve diagnostic efficiency compared with recommended strategies.
文摘Background and Aims:Strategies for detection of early hepatocellular carcinoma(HCC)are still limited.The GALAD score is a serum biomarker-based model designed to predict the probability of having HCC.We aimed to assess the ability of GALAD score to diagnose early HCC and its validity to follow patients after local ablation therapy.Methods:This multicenter prospective study included 108 patients in two groups,58 HCC patients(67 focal lesions)with local ablative therapy(study group),and a control group of 50 patients with liver cirrhosis.The GALAD scores of the study and control groups,and of the HCC patients before and after ablative therapy were compared.Results:Most patients were men(74.1%in study group and 76%in controls)with hepatitis C virus infection(98.30%in the study group,and 94%in controls).GALAD scores were significantly higher in HCC patients than in those with benign cirrhosis(2.65 vs.−0.37,p=0.001).Ablative therapy was successful in 94.4%of focal lesions<2 cm,and in 86.10%of 2–5 cm lesions.The GALAD score was also significantly lower at 1 month after ablation in patients with well-ablated tumors(2.19 vs.0.98,p=0.001).The best cutoff values of GALAD score for diagnosis of early HCC,and for prediction of well ablation of HCC were 0.74 and≤3.31(areas under the curve of 0.92 and 0.75,sensitivities of 84.48%and 76.19%,specificities of 89.13%and 83.33%,positive predictive values of 90.74%and 94.1%,and negative predictive values of 82%and 35.7%respectively).Conclusion:The GALAD score was effective for the diagnosis of early HCC and for followup after ablative therapy.
基金supported by the National Natural Science Foundation of China(Nos 81871949 and 82171834 to H.Z.,No.82273074 to T.Y.)the Jiangsu Six Talent Peaks Project(No.WSN-102 to H.Z.)+1 种基金the Key Research and Development Program of Social Development of Jiangsu Province(No.BE2022725 to H.Z.)the Dawn Project Foundation of Shanghai(No.21SG36 to T.Y.).
文摘Background and aims:The ASAP and GALAD scores are widely used diagnostic models for detecting hepatocellular carcinoma(HCC),incorporating factors such as sex,age,alpha-fetoprotein(AFP),protein induced by vitamin K absence or antagonist-Ⅱ(PIVKA-Ⅱ),and lens culinaris agglutinin-reactive fraction of AFP(AFP-L3%).This study compares the diagnostic efficacy of the ASAP and GALAD scores in the early detection of HCC in patients with non-alcoholic fatty liver disease(NAFLD).Methods:NAFLD patients with and without HCC were recruited from 12 Chinese tertiary hospitals.Serum levels of AFP,PIVKA-II,and AFP-L3%were measured.The diagnostic accuracy of individual biomarkers,the ASAP score,and the GALAD score in detecting NAFLD-HCC at various stages was evaluated using receiver operating characteristic(ROC)curves and area under the curve(AUC)values.Results:In a cohort of 147 NAFLD-HCC cases and 460 NAFLD controls,both the ASAP and GALAD scores outperformed individual biomarkers in detecting NAFLD-HCC.The ASAP score demonstrated a high AUC of 0.910(sensitivity:80.3%,specificity:92.8%)for identifying NAFLD-HCC at all stages,surpassing AFP(AUC:0.716,P<0.001),PIVKA-II(AUC:0.849,P<0.001),AFP-L3%(AUC:0.663,P<0.001),and the GALAD score(AUC:0.882,P?0.014).Comparable results were observed for early-stage NAFLD-HCC and for detecting HCC in NAFLD patients with or without cirrhosis.Conclusion:The ASAP score,which excludes the AFP-L3%indicator,demonstrated superior performance in differentiating NAFLD-HCC compared to the GALAD score,suggesting its potential for early screening of HCC in NAFLD patients.
